These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 9849659)

  • 1. Decahydroisoquinolines: novel competitive AMPA/kainate antagonists with neuroprotective effects in global cerebral ischaemia.
    O'Neill MJ; Bond A; Ornstein PL; Ward MA; Hicks CA; Hoo K; Bleakman D; Lodge D
    Neuropharmacology; 1998; 37(10-11):1211-22. PubMed ID: 9849659
    [TBL] [Abstract][Full Text] [Related]  

  • 2. LY377770, a novel iGlu5 kainate receptor antagonist with neuroprotective effects in global and focal cerebral ischaemia.
    O'Neill MJ; Bogaert L; Hicks CA; Bond A; Ward MA; Ebinger G; Ornstein PL; Michotte Y; Lodge D
    Neuropharmacology; 2000 Jul; 39(9):1575-88. PubMed ID: 10854902
    [TBL] [Abstract][Full Text] [Related]  

  • 3. NMDA receptor antagonism, but not AMPA receptor antagonism attenuates induced ischaemic tolerance in the gerbil hippocampus.
    Bond A; Lodge D; Hicks CA; Ward MA; O'Neill MJ
    Eur J Pharmacol; 1999 Sep; 380(2-3):91-9. PubMed ID: 10513567
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Selective protection against AMPA- and kainate-evoked neurotoxicity by (3S,4aR,6R,8aR)-6-[2-(1(2)H-tetrazole-5-yl)ethyl]decahyd roisoquinoline- 3-carboxylic acid (LY293558) and its racemate (LY215490).
    Schoepp DD; Salhoff CR; Fuson KS; Sacaan AI; Tizzano JP; Ornstein PL; May PC
    J Neural Transm (Vienna); 1996; 103(8-9):905-16. PubMed ID: 9013384
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Locomotor activity detects subunit-selective effects of agonists and decahydroisoquinoline antagonists at AMPA/kainic acid ionotropic glutamate receptors in adult rats.
    O'neill MF; Sanger G; Ornstein PL; Osborne DJ; Woodhouse SM
    Psychopharmacology (Berl); 2005 Apr; 179(1):181-8. PubMed ID: 15821949
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A new pyrrolyl-quinoxalinedione series of non-NMDA glutamate receptor antagonists: pharmacological characterization and comparison with NBQX and valproate in the kindling model of epilepsy.
    Löscher W; Lehmann H; Behl B; Seemann D; Teschendorf HJ; Hofmann HP; Lubisch W; Höger T; Lemaire HG; Gross G
    Eur J Neurosci; 1999 Jan; 11(1):250-62. PubMed ID: 9987029
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of glycine site antagonists of the NMDA receptor in global cerebral ischaemia.
    Hicks CA; Ward MA; Ragumoorthy N; Ambler SJ; Dell CP; Dobson D; O'Neill MJ
    Brain Res; 1999 Feb; 819(1-2):65-74. PubMed ID: 10082862
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synergistic neuroprotective effects by combining an NMDA or AMPA receptor antagonist with nitric oxide synthase inhibitors in global cerebral ischaemia.
    Hicks CA; Ward MA; Swettenham JB; O'Neill MJ
    Eur J Pharmacol; 1999 Sep; 381(2-3):113-9. PubMed ID: 10554878
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Structure-activity relationships in a series of 2(1H)-quinolones bearing different acidic function in the 3-position: 6,7-dichloro-2(1H)-oxoquinoline-3-phosphonic acid, a new potent and selective AMPA/kainate antagonist with neuroprotective properties.
    Desos P; Lepagnol JM; Morain P; Lestage P; Cordi AA
    J Med Chem; 1996 Jan; 39(1):197-206. PubMed ID: 8568808
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Kainate GluR5 receptor subtype mediates the nociceptive response to formalin in the rat.
    Simmons RM; Li DL; Hoo KH; Deverill M; Ornstein PL; Iyengar S
    Neuropharmacology; 1998; 37(1):25-36. PubMed ID: 9680256
    [TBL] [Abstract][Full Text] [Related]  

  • 11. YM90K: pharmacological characterization as a selective and potent alpha-amino-3-hydroxy-5-methylisoxazole-4-propionate/kainate receptor antagonist.
    Shimizu-Sasamata M; Kawasaki-Yatsugi S; Okada M; Sakamoto S; Yatsugi S; Togami J; Hatanaka K; Ohmori J; Koshiya K; Usuda S; Murase K
    J Pharmacol Exp Ther; 1996 Jan; 276(1):84-92. PubMed ID: 8558460
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vitro and in vivo studies in rats with LY293558 suggest AMPA/kainate receptor blockade as a novel potential mechanism for the therapeutic treatment of anxiety disorders.
    Alt A; Weiss B; Ogden AM; Li X; Gleason SD; Calligaro DO; Bleakman D; Witkin JM
    Psychopharmacology (Berl); 2006 Apr; 185(2):240-7. PubMed ID: 16470401
    [TBL] [Abstract][Full Text] [Related]  

  • 13. SPD 502: a water-soluble and in vivo long-lasting AMPA antagonist with neuroprotective activity.
    Nielsen EO; Varming T; Mathiesen C; Jensen LH; Moller A; Gouliaev AH; Wätjen F; Drejer J
    J Pharmacol Exp Ther; 1999 Jun; 289(3):1492-501. PubMed ID: 10336544
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacological characterization of the competitive GLUK5 receptor antagonist decahydroisoquinoline LY466195 in vitro and in vivo.
    Weiss B; Alt A; Ogden AM; Gates M; Dieckman DK; Clemens-Smith A; Ho KH; Jarvie K; Rizkalla G; Wright RA; Calligaro DO; Schoepp D; Mattiuz EL; Stratford RE; Johnson B; Salhoff C; Katofiasc M; Phebus LA; Schenck K; Cohen M; Filla SA; Ornstein PL; Johnson KW; Bleakman D
    J Pharmacol Exp Ther; 2006 Aug; 318(2):772-81. PubMed ID: 16690725
    [TBL] [Abstract][Full Text] [Related]  

  • 15. (3SR,4aRS,6SR,8aRS)-6-(1H-tetrazol-5-yl)decahydroisoquinoline-3-carboxylic acid, a novel, competitive, systemically active NMDA and AMPA receptor antagonist.
    Ornstein PL; Arnold MB; Allen NK; Leander JD; Tizzano JP; Lodge D; Schoepp DD
    J Med Chem; 1995 Dec; 38(25):4885-90. PubMed ID: 8523401
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Are NMDA or AMPA/kainate receptor antagonists more efficacious in the delayed treatment of excitotoxic neuronal injury?
    Prehn JH; Lippert K; Krieglstein J
    Eur J Pharmacol; 1995 Jan; 292(2):179-89. PubMed ID: 7720791
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The synaptic activation of the GluR5 subtype of kainate receptor in area CA3 of the rat hippocampus.
    Vignes M; Bleakman D; Lodge D; Collingridge GL
    Neuropharmacology; 1997; 36(11-12):1477-81. PubMed ID: 9517417
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Negative allosteric modulation of AMPA-preferring receptors by the selective isomer GYKI 53784 (LY303070), a specific non-competitive AMPA antagonist.
    Ruel J; Guitton MJ; Puell JL
    CNS Drug Rev; 2002; 8(3):235-54. PubMed ID: 12353057
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Overactivation of alpha-amino-3-hydroxy-5-methylisoxazole-4-propionate and N-methyl-D-aspartate but not kainate receptors inhibits phosphatidylcholine synthesis before excitotoxic neuronal death.
    Gasull T; DeGregorio-Rocasolano N; Trullas R
    J Neurochem; 2001 Apr; 77(1):13-22. PubMed ID: 11279257
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of intrathecal non-NMDA EAA receptor antagonist LY293558 in rats: a new class of drugs for spinal anesthesia.
    Von Bergen NH; Subieta A; Brennan TJ
    Anesthesiology; 2002 Jul; 97(1):177-82. PubMed ID: 12131120
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.